CIC
HRMY icon

Chase Investment Counsel’s Harmony Biosciences HRMY Stock Holding History

Chase Investment Counsel’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Hold
50,000
– – 0.38% 55
2026
Q1 		$1.4M Buy
50,000
+29,734
+147% +$975K 0.37% 67
2025
Q4 		$758K Buy
+20,266
New +$666K 0.21% 85

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Chase Investment Counsel's HRMY Position: Q2 2026 in Review

Chase Investment Counsel held its Harmony Biosciences (HRMY) position steady in Q2 2026 at 50,000 shares worth $1.82M. The position accounts for 0.38% of the portfolio, ranked #55.

Chase Investment Counsel first reported a position in HRMY in Q4 2025 and has held it in 3 quarters since. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Chase Investment Counsel held 50,000 shares of Harmony Biosciences worth $1.82M as of Q2 2026.
  • Chase Investment Counsel left its Harmony Biosciences share count unchanged in Q2 2026.
  • Harmony Biosciences made up 0.38% of Chase Investment Counsel's portfolio in Q2 2026, its #55 holding.
  • Chase Investment Counsel first reported a position in Harmony Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Chase Investment Counsel's 13F filing for Q2 2026, filed 6 Aug 2026.